Infertility Clinical Trial
Official title:
Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates of Day 3 Embryo Transfer: a Randomized Clinical Trial in Patients Who Underwent in Vitro Fertilization- Embryo Transfer.
Forty-five infertile women undergoing in vitro fertilization treatment were managed by uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer. No statistically significant differences were found in implantation and pregnancy rates when compared with control group.
Study design and sample size This was a randomized clinical trial involving ninety patients
who were undergoing conventional IVF or intracytoplasmic sperm injection (ICSI) treatment at
our Reproductive Medical Center. The subjects were recruited and studied for a period of 6
months between January and June 2008. The study was approved by the Ethics Committee of
Shen-Zhen Maternity and Child Healthcare Hospital. Subjects all signed an informed consent
form.
According to the guideline made by the Ethics Committee of Shen-Zhen Maternity and Child
Healthcare Hospital, we had better accomplish the study within six months. We calculated
that, in our center, a sample size of 100 or more subjects would need to be recruited over
about a 6 months period. We ended up with 90 patients in this study.
Subject Ninety infertile women, aged 23-39 years, with an infertile duration of 3-8 years,
were enrolled from our infertility treatment clinic between January and June 2008. The
selection criteria for participants were only those women who were first going to undergo
IVF or ICSI treatment. Women who were treated with natural cycle IVF or had no appropriate
embryo for ET were excluded. The infertility factors were identified as the following: tubal
(n=54), unexplained (n=3), male n=22), endometriosis (n=9), others (n=2). The selection and
enrollment for each subject was decided by three same physicians. All subjects were informed
that this procedure was a new technique, and that its effectiveness has not been confirmed,
although an optimal outcome in patients with blastocyst transfer was obtained by using this
technique for the same purpose (6). During the selection procedure, four eligible subjects
opted not to participate when counseled about the uncertain of effectiveness, and other two
subjects declined to randomize. Finally, 90 eligible patients were enrolled.
Randomization First, ninety random numbers generated by means of computer were randomly
divided into study group and control group. Then, all subjects in an enrolled date order
were arranged according to the sequence of random numbers. So, ninety subjects were randomly
divided into the study group and control group. The random allocation sequence was concealed
in a closed and dark-colored envelope until the day of oocyte pick-up. Randomization
occurred after patients agreed to participate in the study (Figure 1). All women of two
groups underwent a conventional IVF or ICSI procedure, but in study group, the patients were
added with a uterine cavity injection of day 2 embryo culture supernatant. The IVF or ICSI
procedure was performed by same physicians and laboratory technicians. The treating sequence
of subjects was as same as the enrolling sequence. The study was not blinded, because the
patients as well as the clinicians were aware of the study content.
IVF or ISCI procedure and injection technique of embryo culture supernatant Controlled
ovarian hyperstimulation was performed using a variety of protocols, as previously published
elsewhere (8). A down-regulation of the pituitary was realized during triptorelin
(Triptorelin Acetate Injection, Ferring, Germany) administration S.C., 0.1 mg/d×7, started
from day 21 of the previous cycles. Ovarian stimulation started from day 3 of stimulated
cycle by using recombinant follicle stimulating hormone (rFSH, Gonal-F, Serono,
Switzerland), 225-300IU daily S.C.. The follicle development was monitored by transvaginal
ultrasound scan (TVS). 250ug of HCG (Ovitrelle; Serono, Madrid) was administered by I.M.
when one to two leading follicle(s) reached a mean diameter of 18 mm. In general,
transvaginal oocyte retrieval was performed after 36 h of HCG injection.
The media used for embryo culture was IVF-60. Briefly, after oocyte retrieval (day 0),
cumulus-enclosed oocytes were incubated in IVF-60. Semen was prepared with a 45-90
discontinuous gradient. The resulting pellet was washed in IVF-60. For normal IVF, 100,000
to 150,000 sperm/100ul were used for each oocyte. The maturation stage of oocyte was
assessed for IVF 15-18 hour after insemination (day 1). Cumulus and corona cells were
removed using drawn pipettes. When ICSI was performed, oocytes were denuded with HYASE. Each
mature oocyte was placed in a 6-ul droplet of GAMETE-20. The partner's sperm was placed in a
6-ul droplet of ICSI-100. All droplets were overlaid with OVOIL. ICSI was performed using a
inverted microscope with RI micromanipulators (INTEGRA Micromanipulation System, Research
Instruments, UK). The CO2 incubators (Forma, USA) with 6% CO2 gas were used for embryo
incubation. An embryo scoring system based on cleavage rate and morphologic features was
used for the evaluation of embryo quality, as previously described elsewhere (9). Briefly,
grade 1 is the best score and grade 5 is the worst. For example, a grade 1 embryo has
blastomeres of equal size with no cytoplasmic fragmentation. A grade 2 embryo has symmetric
blastomeres, but a small degree of cytoplasmic fragmentation involving ≤10% of the embryo's
surface. Grades 3 through 5 demonstrate progressive embryo cytoplasmic fragmentation and
variable cell symmetry.
On the day 2, the embryos were translated from the old dish to a new dish with fresh media
and cultured continuously. In study group, the embryo culture supernatant at the old dish
were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into
the patient's uterine cavity. ET was performed on the third day of embryo culture. Two to
three embryos were selected to transfer for each woman. The number of embryos selected for
transfer was based on morphologic criteria and some additional factors, such as duration and
cause of infertility and age of the patient. Pregnancy was determined by carry out a urine
pregnancy test after 14 days of ET. The embryo implantation, the number of gestational sacs,
and embryo heart pulsation were determined by TVS in the seventh week of pregnancy. Except
the day 2 embryo culture supernatant injection, all of the above-mentioned clinical and
laboratory procedures were identical between the study group and control group.
Statistical analysis Baseline characteristics of the patients were expressed as mean
±standard deviation or frequencies and proportion (%). The pregnancy and implantation rates
were calculated based on the cases of pregnancy and number of gestational sacs. A Chi-Square
Test was used to compare the implantation and conception proportions between two groups. The
Statistics Package for Social Science (SPSS 13.0; SPSS Inc.) was used for statistical
analyses. Statistical significance was set at P<0.05.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A |